Shares of Titan Pharmaceuticals Inc. (NASDAQ:TTNP) climbed 34.2 percent to close at $1.65 on Friday after the drugmaker heralded a double-digit increase in shipments of its implantable opioid addiction maintenance product, Probuphine (buprenorphine). Titan, which regained U.S. and Canadian commercial rights to Probuphine from Braeburn Inc. in May 2018, attributed the improvement in part to its recruitment of new commercial and medical affairs personnel, its re-engagement with prescribers and efforts to better identify areas where it can be most successful.